39.60
price up icon1.25%   0.49
after-market Handel nachbörslich: 38.90 -0.70 -1.77%
loading
Schlusskurs vom Vortag:
$39.11
Offen:
$39.43
24-Stunden-Volumen:
514.17K
Relative Volume:
0.59
Marktkapitalisierung:
$1.82B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-14.38
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
+6.62%
1M Leistung:
-5.62%
6M Leistung:
+1.75%
1J Leistung:
-21.11%
1-Tages-Spanne:
Value
$38.83
$39.91
1-Wochen-Bereich:
Value
$37.40
$40.40
52-Wochen-Spanne:
Value
$26.20
$63.50

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name
Firmenname
Apogee Therapeutics Inc
Name
Telefon
650-394-5230
Name
Adresse
221 CRESCENT ST., WALTHAM
Name
Mitarbeiter
196
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
APGE's Discussions on Twitter

Vergleichen Sie APGE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
APGE
Apogee Therapeutics Inc
39.60 2.17B 0 -146.66M -133.21M -2.7541
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-07 Bestätigt BTIG Research Buy
2025-03-13 Eingeleitet Citigroup Buy
2024-11-25 Eingeleitet Canaccord Genuity Buy
2024-05-10 Eingeleitet BofA Securities Buy
2023-12-20 Eingeleitet BTIG Research Buy
2023-08-08 Eingeleitet Guggenheim Buy
2023-08-08 Eingeleitet Jefferies Buy
2023-08-08 Eingeleitet Stifel Buy
2023-08-08 Eingeleitet TD Cowen Outperform
2023-08-08 Eingeleitet Wedbush Outperform
Alle ansehen

Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Apogee Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Apogee Therapeutics Inc. stock priceExtraordinary earning power - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Apogee Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Apogee Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 20, 2025

Teacher Retirement System of Texas Sells 629 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

Will Apogee Therapeutics Inc. stock benefit from interest rate changesTop Gaining Low Risk Assets - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 17, 2025
pulisher
Jul 15, 2025

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Apogee Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Apogee Therapeutics Inc. stock attracts strong analyst attentionLow Risk Stock Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Apogee Therapeutics Inc. stock performs during market volatilityStable Growth Stock Picks - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Insider Monkey

Jul 14, 2025
pulisher
Jul 14, 2025

Analysts Set Apogee Therapeutics Inc. (NASDAQ:APGE) Price Target at $99.00 - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

Rx Rundown: Merck, Gilead Sciences, Apogee Therapeutics and more - Medical Marketing and Media

Jul 11, 2025
pulisher
Jul 10, 2025

Stifel reiterates Buy rating on Apogee Therapeutics stock amid positive AD data - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

Trend Tracker for (APGE) - news.stocktradersdaily.com

Jul 10, 2025
pulisher
Jul 08, 2025

Apogee falls after results from atopic dermatitis trial - MSN

Jul 08, 2025
pulisher
Jul 08, 2025

Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data - Investing.com Canada

Jul 08, 2025
pulisher
Jul 08, 2025

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis (APGE) - Seeking Alpha

Jul 08, 2025
pulisher
Jul 08, 2025

Gold Falls 1%; ProKidney Shares Spike HigherApogee Therapeutics (NASDAQ:APGE), Blue Gold (NASDAQ:BGL) - Benzinga

Jul 08, 2025
pulisher
Jul 08, 2025

Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

Apogee Therapeutics shares fall 1.66% in premarket after profit-taking and technical selling. - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Positive Phase II APEX clinical trial of Apogee’s APG777 - The Pharma Letter

Jul 08, 2025
pulisher
Jul 08, 2025

Apogee Therapeutics’ (APGE) Outperform Rating Reaffirmed at Wedbush - Defense World

Jul 08, 2025
pulisher
Jul 08, 2025

Apogee Therapeutics Target of Unusually Large Options Trading (NASDAQ:APGE) - Defense World

Jul 08, 2025
pulisher
Jul 07, 2025

Apogee Therapeutics stock maintains Buy rating at Citi after positive data - Investing.com India

Jul 07, 2025
pulisher
Jul 07, 2025

Apogee Therapeutics stock maintains Buy rating at Citi after positive data By Investing.com - Investing.com South Africa

Jul 07, 2025

Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):